FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			0	or Section 30(n) or tr	ie irivesi	шеп	Company Ac	01 1940							
1. Name and Address of Reporting Person* WILSON TROY EDWARD				2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]						(Chec	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
,									X	Director					
(Last)	(First)) 3.	3. Date of Earliest Transaction (Month/Day/Year)							Officer (give title below)	below	r (specify v)			
C/O KURA ON	, ,	· .	08/17/2020							President and CEO					
12730 HIGH B	LUFF DRIVE	SUITE 400													
		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)										Line)					
SAN DIEGO	CA									X Form filed by One Reporting Person					
											Form filed by Mo Person	ore than One Re	porting		
(City)	(State)	(Zip)													
		Table I -	Non-Derivativ	e Securities A	cquir	ed, [Disposed (of, or l	Bene	eficially	Owned				
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (I 8)		4. Securities Disposed Of	(D) (Insti			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or	Price	•	Transaction(s)				

	1	(World // Day/ Tear)	٠,					Reported	(1) (111341. 4)	(Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(iiisti. 4)
Common Stock	08/17/2020		G ⁽¹⁾		26,041	D \$0.00 28,096 D		D		
Common Stock	08/17/2020		G ⁽¹⁾		26,041	A	\$0.00	1,795,017	I	by Red Fish Blue Fish Revocable Trust
Common Stock	08/17/2020		S ⁽²⁾		50,000	D	\$22	356,736	I	by Araxes Pharma LLC
Common Stock	08/17/2020		M ⁽³⁾		12,901	A	\$4.8	40,997	D	
Common Stock	08/17/2020		S ⁽³⁾		12,901	D	\$22.0036(4)	28,096	D	
Common Stock	08/18/2020		M ⁽³⁾		521	A	\$4.8	28,617	D	
Common Stock	08/18/2020		S ⁽³⁾		521	D	\$22	28,096	D	
Common Stock	08/19/2020		M ⁽³⁾		11,913	Α	\$4.8	40,009	D	
Common Stock	08/19/2020		S ⁽³⁾		11,913	D	\$22.0932(5)	28,096	D	
Tab	e II - Derivative	Securities Ac	quire	d, Di	isposed of	, or B	eneficially (Owned		

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	umber vative urities uired or oosed O) (Instr. and 5)	6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and of Securiti Underlying Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to purchase common stock	\$4.8	08/17/2020		M ⁽³⁾			12,901	(6)	01/28/2026	Common Stock	12,901	\$0.00	26,162	D	
Option to purchase common stock	\$4.8	08/18/2020		M ⁽³⁾			521	(6)	01/28/2026	Common Stock	521	\$0.00	25,641	D	
Option to purchase common stock	\$4.8	08/19/2020		M ⁽³⁾			11,913	(6)	01/28/2026	Common Stock	11,913	\$0.00	13,728	D	

Explanation of Responses:

- 1. This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities.
- 2. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020.
- 3. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020.
- 4. This transaction was executed in multiple trades at prices ranging from \$22.00 to \$22.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 5. This transaction was executed in multiple trades at prices ranging from \$22.00 to \$22.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 6. This option vested in 48 equal monthly installments commencing on January 29, 2016.

Remarks:

James Basta, Attorney-in-fact

08/19/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.